NCT01403545已完成1 期
Safety, Tolerability and Pharmacokinetics of Liposomal Curcumin in Healthy Volunteers - A Phase I Dose Escalation Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Safety and tolerability of increasing doses of intravenous liposomal Curcumin in healthy subjects by means of adverse events, vital signs and safety laboratory assessments.
研究概览
简要总结
Aim of the present study is:
- To evaluate the safety and tolerability of increasing doses of intravenous liposomal Curcumin in healthy subjects by means of adverse events, vital signs and safety laboratory assessments.
- To investigate the pharmacokinetics of increasing doses of intravenous liposomal Curcumin in healthy subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy male and female subjects.
- •Age between 18-45 years.
- •Body mass index between 18-27 kg/m2
- •Vital signs within the normal range after 5 minutes in supine position (SBP: ≥90 mmHg and ≤140 mmHg, DBP: ≥45 mmHg and ≤90 mmHg, Heart rate: ≥45 bpm and ≤90 bpm).
- •Normal ECG (PR-interval ≤ 210 ms, QRS duration ≤ 140 ms, QTc ≤ 450 ms).
- •Adequate bone marrow function as evidenced by an absolute neutrophil count ≥1500 cells/µl, all normal red blood cell indices, hemoglobin greater than 11 g/dl and a platelet count greater than 150,000/µl.
- •Normal renal function.
- •Normal hepatic function as evidenced by serum total bilirubin ≤1.2 mg/dl, or less than or equal to the upper limit of normal, and alkaline phosphatase less than or equal to the upper limits of normal, and ASAT and ALAT less than or equal to the upper limits of normal.
- •Normal coagulation profile, and activated partial thromboplastin time (aPTT).
- •Normal urine analysis.
- •Signed informed consent.
排除标准
- •Intake of steroids within 2 weeks prior to the first dose of study drug.
- •Concomitant medications (especially anticoagulants and aspirin) or herbal supplements.
- •Active infection, or a fever > 38.5°C within three days prior to the first scheduled day of study drug dosing.
- •Current or past history evidence of disease (e.g. hemolytic diathesis, anemia requiring substitution therapy, hemochromatosis) that could be exacerbated by administration of liposomal curcumin.
- •History of prior malignancy within the past five years except for curatively treated non-melanoma skin cancer or cervical intraepithelial neoplasia.
- •Allergy requiring medical treatment within the last four weeks.
- •Known hypersensitivity to any of the components of turmeric.
- •Participation in another clinical trial within 4 weeks before study initiation.
- •NYHA Class 2 or congestive heart failure, uncontrolled hypertension, or arrhythmias.
- •Positive HIV serology or evidence of active hepatitis.
- •Unstable medical condition or any other medical condition, including mental illness or substance abuse, deemed by the investigator to be likely to interfere with the patient's ability to sign the informed consent form, or his ability to cooperate and participate in the study, or to interfere with the interpretation of the results.
- •History of treated or active seizure disorder or any CNS or PNS neurological disorder.
- •Subjects who are pregnant or breast feeding
研究组 & 干预措施
Liposomal Curcumin
Experimental
Single dose, dose escalation
干预措施: Liposomal Curcumin (Drug)
5% Glucose
Placebo Comparator
干预措施: Placebo (Other)
结局指标
主要结局
Safety and tolerability of increasing doses of intravenous liposomal Curcumin in healthy subjects by means of adverse events, vital signs and safety laboratory assessments.
时间窗: From Baseline until 7 days after the study day
次要结局
- Investigation of the pharmacokinetics of increasing doses of intravenous liposomal Curcumin in healthy subjects.(From Baseline until 48 hours after IMP administration)
研究者
Michael Wolzt, M.D.
Ao. Univ. Prof. Dr.
Medical University of Vienna
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
Dose Escalation Study of Liposomal Paclitaxel With/Without Capecitabine in Patients With Advanced Gastric CarcinomaGastric CarcinomaNCT00639522Nanjing Sike Pharmaceutical Co., Ltd.18
已完成
1 期
Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects by Dermal Application of a LEO 29102Atopic DermatitisNCT01423656LEO Pharma102
Unknown
1 期
A Study to Evaluate the Safety and Efficacy of Docetaxel for Injection (Albumin-bound)in Different Dose Regimens in Patients With Advanced Solid TumorsAdvanced Solid TumorsNCT05114915CSPC ZhongQi Pharmaceutical Technology Co., Ltd.144
已完成
1 期
Single and Multiple Oral Doses of Dabigatran Etexilate in Healthy Chinese SubjectsHealthyNCT02171572Boehringer Ingelheim28
已完成
1 期
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 1356 BS Administered to Healthy Male SubjectsHealthyNCT02173665Boehringer Ingelheim64